648 related articles for article (PubMed ID: 30558615)
21. Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer.
Muzaffar M; Kachare S; Vohra N
Clin Breast Cancer; 2017 Jun; 17(3):e143-e149. PubMed ID: 27998656
[TBL] [Abstract][Full Text] [Related]
22. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
23. Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models.
Rosati R; Oppat K; Huang Y; Kim S; Ratnam M
BMC Cancer; 2020 Jun; 20(1):512. PubMed ID: 32493230
[TBL] [Abstract][Full Text] [Related]
24. Diminished survival in patients with inner versus outer quadrant breast cancers.
Gaffney DK; Tsodikov A; Wiggins CL
J Clin Oncol; 2003 Feb; 21(3):467-72. PubMed ID: 12560437
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
26. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
[TBL] [Abstract][Full Text] [Related]
27. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
29. [Lack of progesterone receptor expression predicts poor prognosis in patients with operable ER-positive invasive breast cancer].
Ma RM; Chen CZ; Lin CQ; Zhang W; Guo GL
Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):687-92. PubMed ID: 27647402
[TBL] [Abstract][Full Text] [Related]
30. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract][Full Text] [Related]
31. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
32. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
34. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in male breast cancer: a population-based study.
Leone JP; Zwenger AO; Iturbe J; Leone J; Leone BA; Vallejo CT; Bhargava R
Breast Cancer Res Treat; 2016 Apr; 156(3):539-548. PubMed ID: 27039306
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
37. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
38. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
39. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up.
Costa SD; Lange S; Klinga K; Merkle E; Kaufmann M
Eur J Cancer; 2002 Jul; 38(10):1329-34. PubMed ID: 12091062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
